Skip to main content

XTL BIOPHARMACEUTICALS LTD

For the period ended Dec 31, 2025. Filed Jun 30, 2026.

View on SEC.gov

About this filing

The yearly report of a company based outside the US. It covers much of what a 10-K does, and may follow accounting rules other than US ones.

FY2025 · Filed Jun 30, 2026

XTLB$1.55-9.4%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits

Cover page

Show cover page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 20-F

(Mark One)

☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31,2025

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

OR

☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________to ___________.

Commission file number:001-36000

(Exact name of registrant as specified in its charter)

N/A

(Translation of Registrant’s Name into English)

Israel

(Jurisdiction of incorporation or organization)

85 Medinat Hayehudim St.

Herzliya,

4676670, Israel

(Address of principal executive offices)

Noam Band

Chief Executive Officer

85 Medinat Hayehudim St.

Herzliya,

4676670, Israel

Tel:+972-54-2288897

(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)

Securities registered or to be registered pursuant to Section 12(b) of the Act:

American Depositary Shares, each representing one hundred Ordinary Shares, par value NIS 0.1XTLBThe Nasdaq Capital Market
(Title of Class)Trading Symbol(Name of each exchange on which registered)

Securities registered or to be registered pursuant to Section 12(g) of the Act: None.

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None.

Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report.

As of December 31, 2025 -946,243,356 Ordinary Shares were issued and outstanding. This number includes 2,365,608 American Depositary Shares and excludes 372,957,973 dormant ordinary shares.

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes ☐No ☒

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Yes ☐No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files.)

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of “large accelerated filer”, “accelerated filer”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer☐Accelerated filer☐
Non-accelerated filer☒Emerging growth company☐

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 13(a) of the Exchange Act. ☐

†The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C.7262(b)) by the registered public accounting firm that prepared or issued its audit report.☐

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

US GAAP ☐International Financial Reporting Standards as issued by the International Accounting Standards Board ☒Other ☐

If “Other” has been check in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.

Item 17 ☐ Item 18 ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No☒

ANNUAL REPORT ON FORM 20-F

TABLE OF CONTENTS

Page
EXPLANATORY NOTE
SPECIAL CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTSii
PART I1
ITEM 1Identity of Directors, Senior Management and Advisers1
ITEM 2Offer Statistics and Expected Timetable1
ITEM 3Key Information1
ITEM 4Information on the Company29
ITEM 4AUnresolved Staff Comments37
ITEM 5Operating and Financial Review and Prospects37
ITEM 6Directors, Senior Management and Employees44
ITEM 7Major Shareholders and Related Party Transactions54
ITEM 8Financial Information56
ITEM 9The Offer and Listing56
ITEM 10Additional Information56
ITEM 11Quantitative and Qualitative Disclosures About Market Risk80
ITEM 12Description of Securities other than Equity Securities81
PART II82
ITEM 13Defaults, Dividend Arrearages and Delinquencies82
ITEM 14Material Modifications to the Rights of Security Holders and Use of Proceeds82
ITEM 15Controls and Procedures82
ITEM 16Reserved83
ITEM 16AAudit Committee Financial Expert83
ITEM 16BCode of Ethics83
ITEM 16CPrincipal Accountant Fees And Services83
ITEM 16DExemptions From The Listing Standards For Audit Committees83
ITEM 16EPurchases Of Equity Securities By The Issuer And Affiliated Purchasers83
ITEM 16FChange In Registrant’s Registered Accountant84
ITEM 16GCorporate Governance84
ITEM 16HMine Safety Disclosure85
ITEM 16IDisclosure Regarding Foreign Jurisdictions that Prevent Inspections85
ITEM 16JInsider Trading Policy85
ITEM 16KCybersecurity85
ITEM 17Financial StatementsF-1
ITEM 18Financial StatementsF-1
ITEM 19Exhibits87
SIGNATURES89

i

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.